TRANSTHERA-B (02617.HK) Financial Statements - Balance Sheet/Income Statement/Cash Flow

Quote List Quote List

Event Tracking

Dec19

Pharmaron-B's New Drug Tengnotinib Application for Market Approval Accepted by CDE

00:23

Dec17

Core product Tengatinib of Yaji Kangang-B publishes exploratory clinical 2 phase results for bile duct cancer

02:37

Dec3

Juventure's Tegavivint receives priority review from NMPA

09:14

Nov18

Yaoke Technology sees significant increase in per share net assets in Q3, secretary explains reasons

11:01

Nov5

Yaojie Health Care Grants Global Development Rights to NLRP3 Inhibitor for $881.5 Million

12:17

Nov3

Jiangke-B Enters into NLRP3 Inhibitor Collaboration Agreement with Neurocrine

00:19

Schedules & Filings

Schedules

Filings

Aug25

Earning Release(CST)

FY2025 Q2 Earning Release (HKD) Net Income -67.24 M, EPS -0.1759

Jun23

IPO(CST)

Listing Price HKD 13.15

Jun9

Earning Release(CST)

FY2024 Q4 Earning Release (HKD) Net Income -60.76 M, EPS -0.1592

Stock List

Top Gainers

Top Decliners

Main Board

Symbol

Price

%Chg

Change